← Leaderboards
Kevin Sean Murnane
Emory University
$3,602,168
Attributed
$8,427,334
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,427,334 · 8
By mechanism
R01$3,381,836 · 2
UG3$3,287,052 · 1
R21$1,203,209 · 3
R41$555,237 · 2
Top collaborators
- Andrew P Escayg7 shared
- Clinton E Canal2 shared
- Adam L Halberstadt2 shared
- Jennifer M Loftis2 shared
- John D Mccorvy2 shared
- Renee Lynn Shirley2 shared
- Martin J. D'Souza1 shared
Most similar at Emory University
Same institution · by research overlap
- Andrew P Escayg$12,950,611
- Christopher Donald Makinson$4,071,363
- Isaac James Bishof$116,144
- Ziyin Tang$74,930
Others in their field
Top investigators on “Receptor”
- Barton F Haynes · Duke University$182,835,224
- James C. Paulson · Scripps Research Institute$84,068,192
- Asrar B. Malik · University Of Illinois At Chicago$55,280,031
- Anthony O Caggiano · Cognition Therapeutics, Inc.$49,563,751
- Robert J Coffey · Vanderbilt University$48,115,270
- Robert H Vonderheide · University Of Pennsylvania$48,030,034
Research focus
ReceptorBrainAcutePharmaceutical PreparationsBehavioralCognitiveFormulationMediatingResistanceAnimal ModelNeuronsCellsBlood - Brain Barrier AnatomyAnimalsBaseMouse ModelPharmacotherapyFebrile ConvulsionsExperimental StudyMortalityEncephalopathiesIon ChannelEpilepsyLife
Grant awards (16)
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder$3,287,052
UG3 · FY2025 · DA
Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder$480,492
R01 · FY2025 · DA
Exploring the role of oxytocin in the regulation of neuronal excitability$470,143
R01 · FY2025 · NS
Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder$509,279
R01 · FY2024 · DA
Exploring the role of oxytocin in the regulation of neuronal excitability$457,373
R01 · FY2024 · NS
Immunotherapeutic Targeting CD74 as a Treatment for Stimulant Use Disorder$405,334
R41 · FY2024 · DA
Exploring the role of oxytocin in the regulation of neuronal excitability$472,869
R01 · FY2023 · NS
Exploring the role of oxytocin in the regulation of neuronal excitability$474,192
R01 · FY2022 · NS
Exploring the role of oxytocin in the regulation of neuronal excitability$517,488
R01 · FY2021 · NS
A nanotechnology approach to higher brain penetrance and sustained brain delivery of intranasal oxytocin$149,903
R41 · FY2018 · DA · contact PI
Receptor pharmacology and toxicology of second-generation pyrrolidine "bath salt" cathinones$223,491
R21 · FY2017 · DA
A novel neuropeptide brain delivery system for epilepsy$193,888
R21 · FY2017 · NS · contact PI
Receptor pharmacology and toxicology of second-generation pyrrolidine "bath salt" cathinones$269,718
R21 · FY2016 · DA
A novel neuropeptide brain delivery system for epilepsy$246,220
R21 · FY2016 · NS · contact PI
Vulnerability biomarkers for cocaine abuse and relapse$2,142
R21 · FY2013 · DA · contact PI
Vulnerability biomarkers for cocaine abuse and relapse$267,750
R21 · FY2012 · DA · contact PI